

Rachel P Rosovsky

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3541101/publications.pdf>

Version: 2024-02-01

96
papers

4,699
citations

236833

25
h-index

106281

65
g-index

123
all docs

123
docs citations

123
times ranked

9397
citing authors

#	ARTICLE	IF	CITATIONS
1	Presentation, Management and Outcomes of Pediatric Pulmonary Embolus. <i>Pediatric Emergency Care</i> , 2022, 38, e475-e481.	0.5	2
2	Assessment of Regional Variability in COVID-19 Outcomes Among Patients With Cancer in the United States. <i>JAMA Network Open</i> , 2022, 5, e2142046.	2.8	9
3	COVID-19 and venous thromboembolism: A narrative review. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2022, 6, e12666.	1.0	16
4	Geriatric risk factors for serious COVID-19 outcomes among older adults with cancer: a cohort study from the COVID-19 and Cancer Consortium. <i>The Lancet Healthy Longevity</i> , 2022, 3, e143-e152.	2.0	16
5	Racial Disparities in COVID-19 Outcomes Among Black and White Patients With Cancer. <i>JAMA Network Open</i> , 2022, 5, e224304.	2.8	43
6	Women's representation in venous thromboembolism randomized trials and registries: The illustrative example of direct oral anticoagulants for acute treatment. <i>Contemporary Clinical Trials</i> , 2022, 115, 106714.	0.8	3
7	Interhospital Transfer for the Management of Acute Pulmonary Embolism. <i>American Journal of Medicine</i> , 2022, 135, 531-535.	0.6	7
8	173: NOVEL COAGULATION TEST SUCCESSFULLY DETECTS ANTICOAGULATION RESISTANCE IN PATIENTS WITH COVID-19. <i>Critical Care Medicine</i> , 2022, 50, 70-70.	0.4	0
9	NCCN Guidelines® Insights: Hematopoietic Growth Factors, Version 1.2022. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2022, 20, 436-442.	2.3	23
10	Sex Differences in Presentation, Risk Factors, Drug and Interventional Therapies, and Outcomes of Elderly Patients with Pulmonary Embolism: Rationale and design of the SERIOUS-PE study. <i>Thrombosis Research</i> , 2022, 214, 122-131.	0.8	3
11	Physician perceptions and use of reduced-dose direct oral anticoagulants for extended phase venous thromboembolism treatment. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2022, 6, e12740.	1.0	1
12	North American Physician Practice Patterns in the Management of Anticoagulation in Pregnancy. <i>Journal of Women's Health</i> , 2021, 30, 829-836.	1.5	3
13	Venous thrombosis, thromboembolism, biomarkers of inflammation, and coagulation in coronavirus disease 2019. <i>Journal of Vascular Surgery: Venous and Lymphatic Disorders</i> , 2021, 9, 835-844.e4.	0.9	14
14	Deep vein thrombosis protocol optimization to minimize healthcare worker exposure in coronavirus disease-2019. <i>Journal of Vascular Surgery: Venous and Lymphatic Disorders</i> , 2021, 9, 299-306.	0.9	9
15	Filter clotting with continuous renal replacement therapy in COVID-19. <i>Journal of Thrombosis and Thrombolysis</i> , 2021, 51, 966-970.	1.0	19
16	Prediction and Prevention of Cancer-Associated Thromboembolism. <i>Oncologist</i> , 2021, 26, e2-e7.	1.9	33
17	Evaluation of direct thrombin inhibitors during a critical heparin shortage. <i>Journal of Thrombosis and Thrombolysis</i> , 2021, 52, 662-673.	1.0	1
18	Venous Thromboembolism: Genetics and Thrombophilias. <i>Seminars in Respiratory and Critical Care Medicine</i> , 2021, 42, 271-283.	0.8	2

#	ARTICLE	IF	CITATIONS
19	Case of right ventricular and aortic thrombi in a patient with severe COVID-19. <i>BMJ Case Reports</i> , 2021, 14, e240745.	0.2	4
20	Temporal Trends in Inpatient Oncology Census Before and During the COVID-19 Pandemic and Rates of Nosocomial COVID-19 Among Patients with Cancer at a Large Academic Center. <i>Oncologist</i> , 2021, 26, e1427-e1433.	1.9	11
21	Impact of Cancer History on Outcomes Among Hospitalized Patients with COVID-19. <i>Oncologist</i> , 2021, 26, 685-693.	1.9	3
22	Thrombosis, Bleeding, and the Observational Effect of Early Therapeutic Anticoagulation on Survival in Critically Ill Patients With COVID-19. <i>Annals of Internal Medicine</i> , 2021, 174, 622-632.	2.0	89
23	Interhospital Transfer of Patients With Acute Pulmonary Embolism. <i>Chest</i> , 2021, 160, 1844-1852.	0.4	19
24	Association of Thrombosis With Hypereosinophilic Syndrome in Patients With Genetic Alterations. <i>JAMA Network Open</i> , 2021, 4, e2119812.	2.8	9
25	The CoVIDâ€TE risk assessment model for venous thromboembolism in hospitalized patients with cancer and COVIDâ€19. <i>Journal of Thrombosis and Haemostasis</i> , 2021, 19, 2522-2532.	1.9	23
26	Comparison of Published Guidelines for the Diagnosis and the Management of Vaccine-Induced Immune Thrombotic Thrombocytopenia. , 2021, 3, e0519.		9
27	Nuts and bolts of COVID-19 associated coagulopathy: the essentials for management and treatment. <i>Postgraduate Medicine</i> , 2021, 133, 1-13.	0.9	4
28	Considerations for Use of Hematopoietic Growth Factors in Patients With Cancer Related to the COVID-19 Pandemic. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2021, 19, 18-21.	2.3	32
29	Practice patterns and outcomes of direct oral anticoagulant use in myeloproliferative neoplasm patients. <i>Blood Cancer Journal</i> , 2021, 11, 176.	2.8	13
30	Pulmonary Hypertension Is Associated with Poor Outcomes in Patients with Myeloproliferative Neoplasms and Cardiovascular Disease. <i>Blood</i> , 2021, 138, 3653-3653.	0.6	2
31	Bleeding Complications in Patients with Cancer and COVID 19- Analysis from the COVID 19and Cancer Consortium (CCC19) Registry. <i>Blood</i> , 2021, 138, 4997-4997.	0.6	0
32	High Incidence of Bleeding Found with Direct Oral Anticoagulant Use in Myeloproliferative Neoplasm Patients. <i>Blood</i> , 2021, 138, 3632-3632.	0.6	3
33	Increased Risk of Thrombosis in Patients with Myeloproliferative Neoplasms Compared with the General Population Hospitalized with COVID-19. <i>Blood</i> , 2021, 138, 1508-1508.	0.6	0
34	A clinical decision framework to guide the outpatient treatment of emergency department patients diagnosed with acute pulmonary embolism or deep vein thrombosis: Results from a multidisciplinary consensus panel. <i>Journal of the American College of Emergency Physicians Open</i> , 2021, 2, e12588.	0.4	3
35	Anticoagulant Reversal Strategies in the Emergency Department Setting: Recommendations of a Multidisciplinary Expert Panel. <i>Annals of Emergency Medicine</i> , 2020, 76, 470-485.	0.3	46
36	Analysis of Partial Thromboplastin Times in Patients With Pulmonary Embolism During the First 48 Hours of Anticoagulation With Unfractionated Heparin. <i>Academic Emergency Medicine</i> , 2020, 27, 117-127.	0.8	21

#	ARTICLE	IF	CITATIONS
37	Anticoagulant acrobatics: Surviving the global heparin shortage in the emergency department. American Journal of Emergency Medicine, 2020, 38, 1291-1293.	0.7	0
38	A low dose heparinized saline protocol is associated with improved duration of arterial line patency in critically ill COVID-19 patients. Journal of Critical Care, 2020, 60, 253-259.	1.0	7
39	Case 35-2020: A 59-Year-Old Woman with Type 1 Diabetes Mellitus and Obtundation. New England Journal of Medicine, 2020, 383, 1974-1983.	13.9	2
40	The Art of Oncology: COVID-19 Era. Oncologist, 2020, 25, 997-1000.	1.9	6
41	Diagnosis and Treatment of Pulmonary Embolism During the Coronavirus Disease 2019 Pandemic. Chest, 2020, 158, 2590-2601.	0.4	59
42	Comparison of published guidelines for management of coagulopathy and thrombosis in critically ill patients with COVID 19: implications for clinical practice and future investigations. Critical Care, 2020, 24, 559.	2.5	78
43	Evaluation of the prothrombin fragment 1.2 in patients with coronavirus disease 2019 (<sc>COVID</sc>â€19). American Journal of Hematology, 2020, 95, 1479-1485.	2.0	24
44	A Systematic Framework to Rapidly Obtain Data on Patients with Cancer and COVID-19: CCC19 Governance, Protocol, and Quality Assurance. Cancer Cell, 2020, 38, 761-766.	7.7	26
45	Direct Oral Anticoagulants for the Treatment of Acute Venous Thromboembolism Associated with Cancer: A Systematic Review and Meta-Analysis. Thrombosis and Haemostasis, 2020, 120, 1128-1136.	1.8	93
46	Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study. Lancet, The, 2020, 395, 1907-1918.	6.3	1,395
47	Special Considerations in Pulmonary Embolism. Critical Care Clinics, 2020, 36, 531-546.	1.0	12
48	COVID-19 and coagulation: bleeding and thrombotic manifestations of SARS-CoV-2 infection. Blood, 2020, 136, 489-500.	0.6	1,021
49	When Pigs Fly: A Multidisciplinary Approach to Navigating a Critical Heparin Shortage. Oncologist, 2020, 25, 334-347.	1.9	10
50	Anticoagulation practice patterns in COVIDâ€19: A global survey. Research and Practice in Thrombosis and Haemostasis, 2020, 4, 969-983.	1.0	35
51	A comprehensive evaluation of apixaban in the treatment of venous thromboembolism. Expert Review of Hematology, 2020, 13, 155-173.	1.0	9
52	Evaluation of andexanet alfa and fourâ€factor prothrombin complex concentrate (4Fâ€PCC) for reversal of rivaroxabanâ€and apixabanâ€associated intracranial hemorrhages. Journal of Thrombosis and Haemostasis, 2020, 18, 1637-1647.	1.9	70
53	A modern reassessment of glycoprotein-specific direct platelet autoantibody testing in immune thrombocytopenia. Blood Advances, 2020, 4, 9-18.	2.5	56
54	NCCN Guidelines Insights: Hematopoietic Growth Factors, Version 1.2020. Journal of the National Comprehensive Cancer Network: JNCCN, 2020, 18, 12-22.	2.3	70

#	ARTICLE	IF	CITATIONS
55	Treatment for Pulmonary Embolism: Anticoagulation Selection and Duration. <i>Respiratory Medicine</i> , 2020, , 57-83.	0.1	0
56	Incidence and Outcomes of Heparin-Induced Thrombocytopenia Associated with a Heparin Shortage at a Large Academic Medical Center. <i>Blood</i> , 2020, 136, 10-10.	0.6	0
57	Filter Clotting with Continuous Renal Replacement Therapy in COVID-19. <i>Blood</i> , 2020, 136, 22-23.	0.6	0
58	Rates of Thrombotic Events in Hypereosinophilic Syndrome and the Effect of Molecular Aberrations in Thrombotic Risk. <i>Blood</i> , 2020, 136, 14-14.	0.6	0
59	Evaluation of the Prothrombin Fragment 1.2 in Patients with COVID-19. <i>Blood</i> , 2020, 136, 4-5.	0.6	0
60	Multicenter Implementation of a Novel Management Protocol Increases the Outpatient Treatment of Pulmonary Embolism and Deep Vein Thrombosis. <i>Academic Emergency Medicine</i> , 2019, 26, 657-669.	0.8	22
61	Extracorporeal membrane oxygenation in acute massive pulmonary embolism: a case series and review of the literature. <i>Perfusion (United Kingdom)</i> , 2019, 34, 22-28.	0.5	61
62	Thromboembolic Risk of 4-Factor Prothrombin Complex Concentrate versus Fresh Frozen Plasma for Urgent Warfarin Reversal in the Emergency Department. <i>Western Journal of Emergency Medicine</i> , 2019, 20, 619-625.	0.6	20
63	<p>Direct oral anticoagulants for treatment and prevention of venous thromboembolism in cancer patients</p>. <i>Vascular Health and Risk Management</i> , 2019, Volume 15, 175-186.	1.0	19
64	Pulmonary embolism response teams: Purpose, evidence for efficacy, and future research directions. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2019, 3, 315-330.	1.0	57
65	Diagnosis, Treatment and Follow Up of Acute Pulmonary Embolism: Consensus Practice from the PERT Consortium. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2019, 25, 107602961985303.	0.7	174
66	Quantitative analysis of desmopressin (DDAVP) response in adult patients with type 1 von Willebrand disease. <i>International Journal of Laboratory Hematology</i> , 2019, 41, 325-330.	0.7	0
67	Changes in treatment and outcomes after creation of a pulmonary embolism response team (PERT), a 10-year analysis. <i>Journal of Thrombosis and Thrombolysis</i> , 2019, 47, 31-40.	1.0	94
68	Pulmonary Embolism Response Teams: Structuring a Dedicated Provider Response to Improve Outcomes for Patients and Institutions. , 2019, 16, .		0
69	Sex Differences in Risk Factors, Clinical Presentation, Treatment and Outcomes of Patients Presenting with Acute Pulmonary Embolism. <i>Blood</i> , 2019, 134, 2429-2429.	0.6	2
70	Urban-Rural Variation in Use of Thrombolytic Therapy for Pulmonary Embolism. <i>Blood</i> , 2019, 134, 3409-3409.	0.6	3
71	Randomized phase 2 study of tivantinib plus erlotinib versus single-agent chemotherapy in previously treated KRAS mutant advanced non-small cell lung cancer. <i>Lung Cancer</i> , 2018, 117, 44-49.	0.9	14
72	Treatment of submassive and massive pulmonary embolism: a clinical practice survey from the second annual meeting of the Pulmonary Embolism Response Team Consortium. <i>Journal of Thrombosis and Thrombolysis</i> , 2018, 46, 39-49.	1.0	19

#	ARTICLE	IF	CITATIONS
73	Venous Thromboembolism: A Survey of Oral Anticoagulant Preferences in the Treatment of Challenging Patient Populations. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2018, 24, 209S-216S.	0.7	6
74	Pulmonary Embolism Response Team. <i>Clinics in Chest Medicine</i> , 2018, 39, 621-630.	0.8	13
75	Contemporary Management and Outcomes of Patients with Massive and Submassive Pulmonary Embolism. <i>American Journal of Medicine</i> , 2018, 131, 1506-1514.e0.	0.6	79
76	The creation and implementation of an outpatient pulmonary embolism treatment protocol. <i>Hospital Practice (1995)</i> , 2017, 45, 123-129.	0.5	12
77	Nuts and bolts of running a pulmonary embolism response team: results from an organizational survey of the National PERTâ„¢ Consortium members. <i>Hospital Practice (1995)</i> , 2017, 45, 76-80.	0.5	31
78	Impact of Pulmonary Arterial Clot Location on Pulmonary Embolism Treatment and Outcomes (90ÂDays). <i>American Journal of Cardiology</i> , 2017, 119, 802-807.	0.7	21
79	Anticoagulation in Pulmonary Embolism: Update in the Age of Direct Oral Anticoagulants. <i>Techniques in Vascular and Interventional Radiology</i> , 2017, 20, 141-151.	0.4	6
80	Case 40-2017. <i>New England Journal of Medicine</i> , 2017, 377, 2581-2590.	13.9	2
81	Comparison of Emergency Department Patients to Inpatients Receiving a Pulmonary Embolism Response Team (<scp>PERT</scp>) Activation. <i>Academic Emergency Medicine</i> , 2017, 24, 814-821.	0.8	17
82	Multidisciplinary pulmonary embolism response teams and systems. <i>Cardiovascular Diagnosis and Therapy</i> , 2016, 6, 662-667.	0.7	20
83	Diversity in the Pulmonary Embolism Response Team Model. <i>Chest</i> , 2016, 150, 1414-1417.	0.4	72
84	Relation Among Clot Burden, Right-Sided Heart Strain, and Adverse Events After Acute Pulmonary Embolism. <i>American Journal of Cardiology</i> , 2016, 118, 1568-1573.	0.7	32
85	The Outpatient Treatment of Venous Thromboembolism: Operational Impact and the Role of Novel Anticoagulants. <i>Seminars in Thrombosis and Hemostasis</i> , 2016, 42, 846-856.	1.5	5
86	A Multidisciplinary Pulmonary Embolism Response Team. <i>Chest</i> , 2016, 150, 384-393.	0.4	195
87	A Comparison of Patients Diagnosed With Pulmonary Embolism Who Are â‰¥65ÂYears With Patients <65ÂYears. <i>American Journal of Cardiology</i> , 2015, 115, 681-686.	0.7	15
88	Quinine-Induced Thrombocytopenia in a Patient With Myocardial Infarction. <i>Journal of Hematology (Brossard, Quebec)</i> , 2015, 4, 137-140.	0.4	0
89	Genotyping Lung Cancer Is an Investment in the Future. <i>Journal of Clinical Oncology</i> , 2014, 32, 3576-3577.	0.8	6
90	Case 36-2013. <i>New England Journal of Medicine</i> , 2013, 369, 2032-2043.	13.9	5

#	ARTICLE	IF	CITATIONS
91	Endothelial stress products and coagulation markers in patients with multiple myeloma treated with lenalidomide plus dexamethasone: an observational study. <i>British Journal of Haematology</i> , 2013, 160, 351-358.	1.2	19
92	Prediction and prevention of thromboembolic events with enoxaparin in cancer patients with elevated tissue factor-bearing microparticles: a randomized-controlled phase II trial (the Microtec) Tj ETQq0 0 0rgBT /Overclock 10 Tf	0.6	10
93	Warfarin-Induced Skin Necrosis in a Patient with Heparin-Induced Thrombocytopenia: Two Diseases or One?. <i>Acta Haematologica</i> , 2008, 120, 117-122.	0.7	12
94	The Incidence of Thrombosis in Patients with Isolated Heparin Induced Thrombocytopenia.. <i>Blood</i> , 2006, 108, 1049-1049.	0.6	2
95	The Identification of Hypercoagulable Markers in Patients with Malignant Gliomas and Venous Thromboembolism.. <i>Blood</i> , 2006, 108, 4097-4097.	0.6	1
96	Catheter-Related Thrombosis in Cancer Patients: Pathophysiology, Diagnosis, and Management. <i>Hematology/Oncology Clinics of North America</i> , 2005, 19, 183-202.	0.9	58